|
Year
|
Drug/site
|
N
|
Excluded/lost
|
Re-infection
|
Uknown
|
LCF
|
LPF
|
ACPR
|
Kaplan–Meier
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
% (95% CI)
|
% (95% CI)
|
% (95% CI)
|
% (95% CI)
|
|---|
|
2011
|
ASAQ
|
|
Ujiji
|
73
|
8 (11.0)
|
12 (16.4)
|
3 (4.1)
|
0 (0.0–7.1)
|
2 (0.1–10.6)
|
98 (89.4–99.9)
|
98.3 (88.8–99.8)
|
|
Kibaha
|
29
|
4 (13.8)
|
NA
|
NA
|
0 (0.0–13.7)
|
0 (0.0–13.7)
|
100 (86.3–100)
|
100
|
|
AL
|
|
Muheza
|
32
|
2 (6.3)
|
0
|
1 (3.1)
|
0 (0.0–11.9)
|
0 (0.0–11.9)
|
100 (88.1–100)
|
100
|
|
2012
|
AL
|
|
Chamwino
|
26
|
3 (11.5)
|
0
|
0
|
0 (0.0–14.8)
|
4.3 (0.1–21.9)
|
95.7 (78.1–99.0)
|
95.7 (72.9–99.4)
|
|
Kyela
|
44
|
8 (18.2)
|
3 (6.8)
|
2 (4.5)
|
6.5 (0.8–21.4)
|
3.2 (0.1–16.7)
|
90.3 (74.2–98.0)
|
91.5 (75.9–97.2)
|
|
Nagaga
|
62
|
23 (37.1)
|
NA
|
NA
|
0 (0.0–9.0)
|
0 (0.0–9.0)
|
100 (91.0–100)
|
100
|
|
2015
|
AL
|
|
Kyela
|
80
|
16 (20.0)
|
3 (3.8)
|
1 (1.3)
|
0 (0.0–6.0)
|
0 (0.0–6.0)
|
100 (94.0–100)
|
100
|
|
DHA-PQ
|
|
Rufiji
|
82
|
10 (12.2)
|
0
|
1 (1.2)
|
0 (0.0–5.1)
|
0 (0.0–5.1)
|
100 (94.9–100)
|
100
|
- Unknown unknown based on PCR analysis, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate/amodiaquine, AL artemether/lumefantrine, DHAPQ dihydroartemisinin/piperaquine
